BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Overview of attention for article published in Journal for Immunotherapy of Cancer, April 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 3,428)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 71 news stories from 71 outlets.

Byondis' Lead IO Therapy Scheduled to Enter Phase I Study This Year NIJMEGEN, Netherlands, April 17, 2023 /PRNewswire/ -…

Byondis' Lead IO Therapy Scheduled to Enter Phase I Study This Year NIJMEGEN, Netherlands, April 17, 2023 /PRNewswire/ -…

Byondis' Lead IO Therapy Scheduled to Enter Phase I Study This Year NIJMEGEN, Netherlands, April 17, 2023 /PRNewswire/ -…

Please enter a search term. Please enter a search term. News provided by Apr 17, 2023, 4:30 AM ET Byondis' Lead IO Therapy…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 67 additional news stories.